Clinical trial · Interventional
Antisecretory Factor Glioblastoma Phase 2
Antisecretory Factor During Concomitant and Adjuvant Therapy of Primary Glioblastoma, a Randomised, Prospective and Double Blinded Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo egg yolk powder | Dietary Supplement | — | UNRESOLVED |
| Salovum | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Salovum
- description
- Salovum, an egg yolk powder will be orally at dose of 11 g 3 times daily.
- interventionNames
- Dietary Supplement: Salovum
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo, an egg yolk powder will be orally at dose of 11 g 3 times daily.
- interventionNames
- Dietary Supplement: Placebo egg yolk powder
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- up to 12 months from primary surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathology verified glioblastoma or astrocytoma grade 4 2. Age 18-75 years 3. Surgical treatment-resection. 4. Scheduled concomitant radiochemotherapy, or only chemotherapy. 5. Informed consent Exclusion Criteria: 1. No informed consent 2. Egg yolk allergy 3. Only surgical biopsy 4. Only radiotherapy
References
Publications (1)
- DERIVEDEhinger E, Darabi A, Visse E, Edvardsson C, Tomasevic G, Cederberg D, Kinhult S, Rydelius A, Nilsson C, Belting M, Bengzon J, Siesjo P. Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial. Trials. 2025 Mar 13;26(1):86. doi: 10.1186/s13063-025-08792-z. PMID 40083039